Avalo Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDAvalo Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is weak (RS Rating: 42), showing significant lag compared to the market leaders. Earnings growth of 22% provides fundamental context to the price action. Investors should exercise caution due to high volatility (91% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $14.76 | +20.82% | ABOVE |
| 50 SMA | $15.58 | +14.43% | ABOVE |
| 100 SMA | $15.52 | +14.90% | ABOVE |
| 150 SMA | $16.16 | +10.32% | ABOVE |
| 200 SMA | $15.63 | +14.05% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is AVTX in an uptrend right now?
AVTX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is AVTX overbought or oversold?
AVTX's RSI (14) is 61. The stock is in neutral territory, neither overbought nor oversold.
Is AVTX outperforming the market?
AVTX has a Relative Strength (RS) Rating of 42 out of 99. AVTX is currently lagging the broader market.
Where is AVTX in its 52-week range?
AVTX is trading at $17.83, which is 74% of its 52-week high ($24.25) and 67% above its 52-week low ($4.50).
How volatile is AVTX?
AVTX has a Beta of 1.56 and 52-week volatility of 91%. It's more volatile than the S&P 500 - expect bigger swings.